Article

Relationship between the Blood Urea Nitrogen to Creatinine Ratio and In-Hospital Mortality in Non-Traumatic Subarachnoid Hemorrhage Patients: Based on Propensity Score Matching Method

Zirong Chen †, Junhong Wang †, Hongkuan Yang, Hua Li, Rudong Chen * and Jiasheng Yu *

Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
* Correspondence: rudongchen@tjh.tjmu.edu.cn (R.C.); yujiasheng2000@tjh.tjmu.edu.cn (J.Y.)
† These authors contributed equally to this work.

Abstract: (1) Background: To explore the correlation between the blood urea nitrogen to creatinine ratio (UCR) and in-hospital mortality in non-traumatic subarachnoid hemorrhage patients. (2) Methods: Specific clinical information was collected from the Medical Information Mart for Intensive IV (MIMIC-IV) database. The optimal cut-off value of the UCR was calculated with ROC curve analysis conducted using the maximum Youden index for the prediction of survival status. Univariable and multivariable logistic regression analyses were also carried out to assess the prognostic significance of UCR, and the Kaplan–Meier (K–M) analysis was conducted to draw the survival curves. Then, the 1:1 propensity score matching (PSM) method was applied to improve the reliability of the research results while balancing the unintended influence of underlying confounders. (3) Results: This retrospective cohort study included 961 patients. The optimal cut-off value of the UCR for in-hospital mortality was 27.208. The PSM was performed to identify 92 pairs of score-matched patients, with balanced differences exhibited for nearly all variables. According to the K–M analysis, those patients with a UCR of more than 27.208 showed a significantly higher level of in-hospital mortality compared to the patients with a UCR of less than 27.208 (p < 0.05). After the adjustment for possible confounders, those patients whose UCR was more than 27.208 still had a significantly higher level of in-hospital mortality than the patients whose UCR was less than 27.208, as revealed by the multivariable logistic regression analysis (OR = 3.783, 95% CI: 1.959~7.305, p < 0.001). Similarly, the in-hospital mortality remained substantially higher for those patients in the higher UCR group than for the patients in the lower UCR group after PSM. (4) Conclusion: A higher level of the UCR was evidently associated with an increased risk of in-hospital mortality, which made the ratio useful as a prognostic predictor of clinical outcomes for those patients with non-traumatic subarachnoid hemorrhage.

Keywords: non-traumatic subarachnoid hemorrhage; blood urea nitrogen to creatinine ratio; in-hospital mortality; MIMIC-IV database

1. Introduction

Non-traumatic subarachnoid hemorrhage is a neurological emergency mainly caused by the rupture of intracranial aneurysms. It requires timely diagnosis and effective management to prevent life-threatening rebleeding and improve the prognosis. The incidence of rebleeding can be effectively controlled by surgical clipping or endovascular therapy. Although the mortality rate for aneurysmal subarachnoid hemorrhage has decreased significantly in the past decade, the rate remains higher than 30% [1]. Given the risk of subarachnoid hemorrhage, it is necessary to find non-invasive and inexpensive tests to identify those at greater risk of death and to further reduce the mortality rate.
Blood urea nitrogen (BUN) is produced by the liver and excreted by the kidneys. It is a biomarker that can reflect the function of the liver and kidneys. Recently, it was reported that the BUN level is an effective prognostic factor for many cases, including ischemic stroke [2], chronic obstructive pulmonary disease [3], cardiogenic shock [4], acute ST-elevation myocardial infarction [5], neonatal sepsis [6], and bone marrow transplants [7]. The level of creatinine is commonly used to reflect the renal function, which can help to judge whether the renal function is in a stage of potential failure or improvement [8]. However, the level of BUN and creatinine can be affected by many factors, such as the use of corticosteroids, protein intake, and dehydration. Therefore, the BUN/creatinine ratio (UCR) is a relatively useful parameter, which can reduce the effect of the above factors. In recent studies, it was reported that an elevated UCR is a poor prognosis factor for patients with septic shock [8], ischemic stroke [2,9,10], acute heart failure [11], and chronic heart failure [12].

To our knowledge, this is the first study to assess the relationship between the UCR and in-hospital mortality of subarachnoid hemorrhage patients. Therefore, the present study is aimed at exploring the prognostic significance of the UCR in subarachnoid hemorrhage patients and providing a simple and convenient indicator for high-risk patients.

2. Materials and Methods

2.1. Data Sources

We extracted data from the Medical Information Mart for Intensive Care (MIMIC-IV) [13], a free and publicly available database. We were allowed to extract data after we completed the training courses regulated by the National Institutes of Health (NIH) and the Protecting Human Research Participants examination. One author, Junhong Wang, was approved to utilize the database. Our study was also approved by the Institutional Review Boards of Beth Israel Deaconess Medical Center and the Massachusetts Institute of Technology (Cambridge, MA, USA). Additional ethical approval was not needed. The findings of this study are reported following the Strengthening the Reporting of Observational Studies in Epidemiology guidelines [14].

2.2. Study Population

A total of 1277 patients with non-traumatic subarachnoid hemorrhage were selected. The diagnosis of subarachnoid hemorrhage was based on the International Classification of Disease, Ninth and Tenth Revision. We selected patients who met the following standards: (1) those who were first admitted to the ICU; (2) those whose age was over 18 years; and (3) those who finished a UCR examination in the first 24 h of being admitted to the ICU. ICU patients with length of stay was less than 24 h also excluded to avoid potential extremum value influence. We excluded patients according the following standard: the length of ICU stay was less than 24 h. Thus, only 961 patients were included in this study. The workflow is shown in Figure 1.

2.3. Data Extraction

We extracted variables from the MIMIC-IV database: (1) demographics: sex, age, and ethnicity; (2) vital signs: systolic blood pressure (SBP), respiratory rate (RR), heart rate (HR), diastolic blood pressure (DBP), temperature, and percutaneous oxygen saturation (SpO2); (3) comorbidities: myocardial infarction, congestive heart failure (CHF), chronic pulmonary disease (CPD), delayed cerebral ischemia (DCI), peripheral vascular disease, mild liver disease, diabetes, etc.; (4) laboratory results: white blood cell count (WBC), international normalized ratio (INR), neutrophil count, monocyte count, activated partial thromboplastin time (APTT), prothrombin time (PT), and aspartate transaminase (AST). In addition, the first laboratory test results for blood urea nitrogen and creatinine values after ICU admission were extracted as the interest variable and the major exposure factor in this study. The sequential organ failure assessment (SOFA) score, Oxford Acute Severity of
Illness Score (OASIS), World Federation of Neurosurgical Societies (WFNS), and Glasgow Coma Scale (GCS) were considered to measure the admission severity.

2.4. Endpoints

The primary outcome was in-hospital mortality. The secondary outcomes were the ICU stay length and hospital stay length.

2.5. Statistical Analysis

The continuous variables were displayed as the average ± standard deviation (SD) or the mid-value (interquartile range). The Student’s t-test or Mann–Whitney U-test was used according to the normality of the data distribution. Categorical variables were displayed as a case quantity (%), and the chi-square test (or Fisher’s exact approach) was utilized for analyses.

The optimal cut-off value of the UCR was calculated with ROC curve analysis conducted using the maximum Youden index for the prediction of survival status. The Youden index = sensitivity + specificity – 1. The UCR was divided into two groups based on the cut-off value.

Univariable and multivariable regression analyses were carried out to assess the prognostic significance of the UCR. The screening criteria for confounders included: (1) a factor affected the research variable (with impact over 10%); (2) the outcome variables might be obviously impacted by some factors based on previous experiences; and (3) the univariable analysis revised the variables, with p less than 0.05.

The crude model did not adjust any of the variables. In the multivariable analysis, we performed different statistical models to verify the stability of the results. Model I made adjustments to the variables of age, gender, and ethnicity. Model II made adjustments to 6 variables, including myocardial infarction, congestive heart failure, renal disease, mild liver disease, diabetes, and sepsis. Model III made further adjustments to 15 variables, including HR, RR, platelets, WBC, anion-gap, bicarbonate, chloride, sodium, INR, PT, APTT, OASIS, GCS, WFNS, and SOFA.
Given the difficulty of achieving complete stochasticity for the screening of patients, the PSM approach was used to balance the influence of selection bias and underlying confounders. The PSM analysis was conducted with the logistic regression model developed using age, sex, ethnicity, HR, DBP, MBP, temperature, etc. A standardized mean difference (SMD) was used to examine the PSM degree, and a lower threshold than 0.1 was treated as acceptable. For the pairs of patients with a low UCR (<27.208) and a high UCR (≥27.208), 1:1 matching was performed with a caliper of 0.1. Finally, 184 propensity score-matched patients and 92 pairs of score-matched patients were identified.

The estimated propensity scores were used as weights. Pairwise algorithmic (PA) [15], standardized mortality ratio weight (SMRW) [16], inverse probability of treatment weight (IPTW), [17] and overlap weight (OW) [18] were used to generate a weighted cohort to adjust the baseline confounders. The weighted cohort could accurately reflect the independent association between the UCR and in-hospital mortality.

The subgroup analysis was conducted to determine how the UCR affected the in-hospital mortality from various perspectives including age (<65 and ≥65 years old), sex, myocardial infarction, congestive heart failure, peripheral vascular disease, chronic pulmonary disease, renal disease, malignant cancer, mild liver disease, diabetes, SOFA (<3 and ≥3), sepsis, and WFNS grade. We conducted the subgroup analyses using a logistic regression model.

The statistic program packages R 3.3.2 (http://www.R-project.org, The R Foundation) and Free Statistics software version 1.4 (Beijing, China) were used to complete all analyses. The study carried out a two-tailed test and \( p < 0.05 \) was statistical significance.

### 3. Results

#### 3.1. Data Sources

We selected patients who met the preset standards (see Figure 1 for a flow chart).

#### 3.2. Clinical Characteristics of Study Subjects

Table 1 compares the demographic data, vital signs, comorbidities, treatment, laboratory results, scores, and outcomes between the survivor and non-survivor patient groups. Overall, the median age of patients was 60.0 years old, and approximately 56.0% were women. The non-survivor group presented a higher UCR than the survivor group (median: 18.0 vs. 16.7, respectively, \( p = 0.006 \)). Compared to the survivor group, the non-survivor group was older (68.0 vs. 58.5 years old, respectively, \( p < 0.001 \)), and presented a higher comorbidity incidence of myocardial infarction, congestive heart failure, chronic pulmonary disease, renal disease, malignant cancer, mild liver disease, diabetes, sepsis as well as higher OASIS and lower GCS scores (all \( p \) values < 0.05). The levels of urea nitrogen, creatinine, INR, PT, APTT, glucose, WBC, and anion gap in non-survivor group were significantly higher than survivor group (Table 1).

| Variables                  | Total (n = 961) | Survival (n = 772) | Non-Survival (n = 189) | \( p \)-Value |
|----------------------------|----------------|--------------------|------------------------|--------------|
| **Demographic**            |                |                    |                        |              |
| Female, n (%)              | 538 (56.0)     | 438 (56.7)         | 100 (52.9)             | 0.342        |
| Age, years                 | 60.0 (51.0, 72.0) | 58.5 (50.0, 70.0) | 68.0 (56.0, 79.0)      | <0.001       |
| Ethnicity, n (%)           |                |                    |                        |              |
| Asian                      | 36 (3.7)       | 23 (3)             | 13 (6.9)               | <0.001       |
| White                      | 580 (60.4)     | 499 (64.6)         | 81 (42.9)              |              |
| Other                      | 345 (35.9)     | 250 (32.4)         | 95 (50.3)              |              |
| **Vital signs**            |                |                    |                        |              |
| HR, beats/minute           | 78.0 (71.0, 87.0) | 77.0 (70.0, 86.0) | 82.0 (75.0, 92.0)      | <0.001       |
| SBP, mmHg                  | 125.0 (115.0, 133.0) | 125.0 (115.0, 133.0) | 126.0 (116.0, 134.0) | 0.741        |
| DBP, mmHg                  | 64.0 (58.0, 69.0) | 64.0 (58.0, 69.0) | 62.0 (57.0, 70.0)      | 0.136        |
| MBP, mmHg                  | 82.0 (76.0, 88.0) | 82.0 (76.0, 88.0) | 81.0 (76.0, 88.0)      | 0.582        |
### Table 1. Cont.

| Variables | Total (n = 961) | Survival (n = 772) | Non-Survival (n = 189) | p-Value |
|-----------|----------------|-------------------|-----------------------|---------|
| RR, times/minute | 18.0 (16.0, 20.0) | 17.0 (16.0, 19.0) | 19.0 (17.0, 21.0) | <0.001 |
| Temperature, °C | 37.0 (36.8, 37.3) | 37.0 (36.8, 37.2) | 37.0 (36.6, 37.5) | 0.842 |
| SpO2, % | 98.0 (96.0, 99.0) | 98.0 (96.0, 99.0) | 98.0 (97.0, 99.0) | 0.001 |
| Comorbidities, n (%) | | | | |
| Myocardial infarction | 80 (8.3) | 56 (7.3) | 24 (12.7) | 0.015 |
| Congestive heart failure | 88 (9.2) | 61 (7.9) | 27 (14.3) | 0.006 |
| Peripheral vascular disease | 93 (9.7) | 79 (10.2) | 14 (7.4) | 0.239 |
| Chronic pulmonary disease | 141 (14.7) | 105 (13.6) | 36 (19) | 0.058 |
| Peptic ulcer disease | 6 (0.6) | 4 (0.5) | 2 (1.1) | 0.336 |
| Paraplegia | 156 (16.2) | 124 (16.1) | 32 (16.9) | 0.772 |
| Renal disease | 77 (8.0) | 45 (5.8) | 32 (16.9) | <0.001 |
| Malignant cancer | 37 (3.9) | 26 (3.4) | 11 (5.8) | 0.116 |
| Mild liver disease | 43 (4.5) | 23 (3) | 6 (3.2) | 0.025 |
| Diabetes | 486 (50.6) | 124 (16.1) | 132 (69.8) | <0.001 |
| Laboratory results | | | | |
| Urea nitrogen, mg/dL | 13.0 (10.0, 18.0) | 13.0 (10.0, 17.0) | 18.0 (13.0, 28.0) | <0.001 |
| Creatinine, mg/dL | 0.8 (0.6, 1.0) | 0.8 (0.6, 0.9) | 1.0 (0.7, 1.3) | <0.001 |
| UCR | 17.0 (13.3, 21.8) | 16.7 (13.3, 21.4) | 18.0 (13.8, 25.0) | 0.006 |
| Hemoglobin, g/L | 12.9 (11.6, 14.1) | 13.0 (11.8, 14.2) | 12.5 (10.9, 14.1) | 0.032 |
| Platelets, 10^9/L | 227.0 (184.0, 280.0) | 230.0 (189.0, 281.0) | 219.0 (152.0, 272.0) | <0.001 |
| WBC, 10^9/L | 12.9 (9.7, 16.6) | 12.5 (9.4, 15.9) | 15.2 (11.6, 19.7) | <0.001 |
| Anion gap, mmol/L | 16.0 (14.0, 18.0) | 16.0 (14.0, 18.0) | 18.0 (15.0, 20.0) | <0.001 |
| Bicarbonate, mmol/L | 24.0 (22.0, 26.0) | 24.0 (22.0, 26.0) | 23.0 (21.0, 26.0) | 0.039 |
| Calcium, mg/dL | 8.7 (8.3, 9.2) | 8.7 (8.4, 9.1) | 8.7 (8.2, 9.2) | 0.855 |
| Chloride, mmol/L | 107.0 (104.0, 110.0) | 107.0 (104.0, 109.0) | 109.0 (105.0, 116.0) | <0.001 |
| Sodium, mmol/L | 141.0 (139.0, 144.0) | 141.0 (139.0, 143.0) | 144.0 (140.0, 149.0) | <0.001 |
| INR | 1.1 (1.1, 1.2) | 1.1 (1.1, 1.2) | 1.2 (1.1, 1.4) | <0.001 |
| PT, s | 12.6 (11.8, 13.8) | 12.5 (11.7, 13.5) | 13.6 (12.3, 15.8) | <0.001 |
| APTT, s | 29.0 (26.1, 33.5) | 28.7 (25.9, 32.8) | 30.2 (26.8, 37.2) | 0.003 |
| ALT, IU/L | 78.0 (52.0, 78.0) | 78.0 (42.0, 78.0) | 78.0 (25.0, 78.0) | 0.007 |
| AST, U/L | 127.0 (45.0, 127.0) | 127.0 (52.0, 127.0) | 127.0 (37.0, 127.0) | 0.118 |
| Glucose, mg/dL | 131.5 (112.5, 156.3) | 128.0 (109.8, 150.0) | 151.6 (126.0, 187.8) | <0.001 |
| Scores | | | | |
| OASIS | 31.0 (25.0, 40.0) | 29.0 (23.0, 37.0) | 41.0 (35.0, 46.0) | <0.001 |
| GCS | 13.0 (7.0, 14.0) | 13.0 (8.0, 14.0) | 7.0 (3.0, 15.0) | <0.001 |
| SOFA | 3.0 (2.0, 3.0) | 3.0 (2.0, 3.0) | 3.0 (2.0, 4.0) | 0.001 |
| WFNS Grade, n (%) | | | | |
| I | 152 (15.8) | 100 (13) | 52 (27.5) | <0.001 |
| II | 315 (32.8) | 308 (39.9) | 7 (3.7) | <0.001 |
| IV | 14 (1.5) | 14 (1.8) | 0 (0) | <0.001 |
| V | 212 (22.1) | 186 (24.1) | 26 (13.8) | <0.001 |
| Outcomes | | | | |
| Length of ICU stay, days | 12.0 (7.0, 20.0) | 13.0 (8.0, 21.0) | 5.0 (2.0, 13.0) | <0.001 |
| Length of hospital stay, days | 7.0 (3.0, 13.0) | 7.0 (3.0, 13.0) | 4.0 (2.0, 10.0) | <0.001 |

### 3.3. The Prognostic Significance of UCR before PSM

The ROC curve of the UCR was plotted, and the AUC was 0.564 (95% CI, 0.515–0.613) (Figure S1). The best cut-off value of the UCR was calculated with ROC curve analysis, using the highest Youden index to predict the survival status, where the Youden index = sensitivity + specificity – 1. The corresponding optimal cut-off value was 27.208, the evaluation sensitivity was 21.7%, and the specificity was 29.0% (Table S1). Based on the cut-off value, 961 patients were divided into the low UCR (<27.208, n = 865) group and the high UCR (≥27.208, n = 96) group. The demographics, coexisting diseases, vital signs, scoring,
laboratory results, etc. are presented in Table 2. Compared to patients in the low UCR (<27.208) group, patients in the high UCR (≥27.208) group were at higher risk of in-hospital mortality (42.7 vs. 17.1%, respectively, \( p < 0.001 \)) and had a higher comorbidity incidence for myocardial infarction, congestive heart failure, dementia, renal disease, malignant cancer, and diabetes (\( p < 0.05 \)) (Table 2).

Table 2. The clinical characteristics of non-traumatic subarachnoid hemorrhage patients before PSM.

| Characteristic | All Patients | Low UCR < 27.208 | High UCR ≥ 27.208 | \( p \) |
|---------------|--------------|------------------|-------------------|------|
| N             | 961          | 865              | 96                |      |
| Demographic   |              |                  |                   |      |
| Female, n (%) | 538 (56.0)   | 472 (54.6)       | 66 (68.8)         | 0.008|
| Age, years    | 60.0 (51.0, 72.0) | 59.0 (50.0, 70.0) | 74.0 (61.0, 80.0) | <0.001|
| Ethnicity, n (%) |             |                  |                   | 0.161|
| Asian         | 36 (3.7)     | 29 (3.4)         | 7 (7.3)           |      |
| White         | 580 (60.4)   | 522 (60.3)       | 58 (60.4)         |      |
| Other         | 345 (35.9)   | 314 (36.3)       | 31 (32.3)         |      |
| Vital signs   |              |                  |                   |      |
| HR, beats/minute | 78.0 (71.0, 87.0) | 78.0 (70.0, 87.0) | 81.5 (71.0, 92.0) | 0.047|
| SBP, mmHg     | 125.0 (115.0, 133.0) | 125.0 (115.0, 133.0) | 124.5 (116.0, 132.2) | 0.523|
| DBP, mmHg     | 64.0 (58.0, 69.0) | 64.0 (58.0, 70.0) | 60.0 (55.8, 66.0) | <0.001|
| MBP, mmHg     | 82.0 (76.0, 88.0) | 82.0 (76.0, 88.0) | 78.0 (75.0, 83.0) | <0.001|
| RR, times/minute | 18.0 (16.0, 20.0) | 18.0 (16.0, 20.0) | 18.5 (17.0, 20.0) | 0.015|
| Temperature, °C | 37.0 (36.8, 37.3) | 37.0 (36.8, 37.3) | 36.9 (36.7, 37.1) | 0.013|
| SpO2, %       | 98.0 (96.0, 99.0) | 98.0 (96.0, 99.0) | 98.0 (96.0, 99.0) | 0.571|
| Comorbidities, n (%) |      |                  |                   |      |
| Myocardial infarction | 80 (8.3) | 67 (7.7) | 13 (13.5) | 0.051|
| Congestive heart failure | 88 (9.2) | 66 (7.6) | 22 (22.9) | <0.001|
| Peripheral vascular disease | 93 (9.7) | 88 (10.2) | 5 (5.2) | 0.119|
| Dementia      | 17 (1.8)     | 12 (1.4)         | 5 (5.2)           | 0.021|
| Paraplegia    | 156 (16.2)   | 147 (17)         | 9 (9.4)           | 0.055|
| Renal disease | 77 (8.0)     | 59 (6.8)         | 18 (18.8)         | <0.001|
| Malignant cancer | 37 (3.9) | 29 (3.4) | 8 (8.3) | 0.025|
| Mild liver disease | 43 (4.5) | 35 (4) | 8 (8.3) | 0.066|
| Diabetes      | 161 (16.8)   | 129 (14.9)       | 32 (33.3)         | <0.001|
| DCI           | 66 (6.9)     | 64 (7.4)         | 2 (2.1)           | 0.051|
| Sepsis        | 486 (50.6)   | 429 (49.6)       | 57 (59.4)         | 0.069|
| Vasospasm, n (%) | 80 (8.3) | 77 (8.9) | 3 (3.1) | 0.052|
| Laboratory results |     |                  |                   |      |
| Hemoglobin, g/L | 12.9 (11.6, 14.1) | 13.0 (11.7, 14.2) | 12.2 (10.3, 13.6) | <0.001|
| Platelets, \( \times 10^9 \)/L | 227.0 (184.0, 280.0) | 229.0 (187.0, 283.0) | 209.5 (154.8, 251.2) | <0.001|
| WBC, \( \times 10^9 \)/L | 12.9 (9.7, 16.6) | 12.9 (9.6, 16.6) | 12.4 (9.9, 16.9) | 0.688|
| Anion gap, mmol/L | 16.0 (14.0, 18.0) | 16.0 (14.0, 18.0) | 16.0 (14.8, 19.0) | 0.095|
| Bicarbonate, mmol/L | 24.0 (22.0, 26.0) | 24.0 (22.0, 26.0) | 25.0 (23.0, 26.0) | 0.083|
| Calcium, mg/dL | 8.7 (8.3, 9.2) | 8.7 (8.3, 9.2) | 8.8 (8.3, 9.3) | 0.478|
| Chloride, mmol/L | 107.0 (104.0, 110.0) | 107.0 (104.0, 110.0) | 107.0 (103.0, 112.0) | 0.919|
| Sodium, mmol/L | 141.0 (139.0, 144.0) | 141.0 (139.0, 143.0) | 141.0 (138.0, 146.0) | 0.520|
| INR           | 1.1 (1.1, 1.2) | 1.1 (1.1, 1.2) | 1.2 (1.1, 1.4) | <0.001|
| PT, s         | 12.6 (11.8, 13.8) | 12.6 (11.7, 13.7) | 13.2 (12.0, 15.3) | 0.003|
| APTT, s       | 29.0 (26.1, 33.5) | 28.9 (26.0, 33.2) | 29.5 (26.6, 34.7) | 0.406|
| ALT, IU/L     | 78.0 (32.0, 78.0) | 78.0 (32.0, 78.0) | 78.0 (31.8, 78.0) | 0.686|
| AST, U/L      | 127.0 (45.0, 127.0) | 127.0 (45.0, 127.0) | 127.0 (43.8, 127.0) | 0.443|
| Glucose, mg/dL | 131.5 (112.5, 156.3) | 131.3 (112.0, 154.3) | 135.1 (116.5, 169.6) | 0.097|
| Scores        |              |                  |                   |      |
| SOFA          | 3.0 (2.0, 3.0) | 3.0 (2.0, 3.0) | 3.0 (2.8, 3.0) | 0.162|
| GCS           | 13.0 (7.0, 14.0) | 13.0 (7.0, 14.0) | 10.0 (6.0, 13.0) | 0.006|
| OASIS         | 31.0 (25.0, 40.0) | 31.0 (24.0, 39.0) | 37.5 (29.8, 44.0) | <0.001|
Table 2. Cont.

| Characteristic | Before PSM |  |  |  |  |
|----------------|------------|----------------|----------------|----------------|----------------|
| WFNS, n (%)    |            |                |                |                | 0.01           |
| I              | 152 (15.8) | 138 (16)       | 14 (14.6)      |                |                |
| II             | 315 (32.8) | 296 (34.2)     | 19 (19.8)      |                |                |
| III            | 14 (1.5)   | 11 (1.3)       | 3 (3.1)        |                |                |
| IV             | 212 (22.1) | 190 (22)       | 22 (22.9)      |                |                |
| V              | 268 (27.9) | 230 (26.6)     | 38 (39.6)      |                |                |
| Outcomes       |            |                |                |                |                |
| In-hospital mortality, n (%) | 189 (19.7) | 148 (17.1) | 41 (42.7) | <0.001 |
| Length of ICU stay, days   | 12.0 (7.0, 20.0) | 12.0 (7.0, 20.0) | 11.0 (5.0, 19.0) | 0.195 |
| Length of hospital stay, days | 7.0 (3.0, 13.0) | 7.0 (3.0, 13.0) | 5.5 (2.0, 11.2) | 0.093 |

3.4. Association between UCR and in-Hospital Mortality in Non-Traumatic Subarachnoid Hemorrhage Patients before PSM

Tables S2 and 3 list the univariable and multivariable logistic analysis results separately. Table 3 shows an unadjusted and a multivariable-adjusted correlation between the UCR and in-hospital mortality.

Table 3. Multivariable logistic regression analyses for in-hospital mortality in patients with non-traumatic subarachnoid hemorrhage.

| Characteristic | Before PSM |  |  |  |  |
|----------------|------------|----------------|----------------|----------------|----------------|
| Crude Model    | OR (95% CI) | p-Value | OR (95% CI) | p-Value | OR (95% CI) | p-Value | OR (95% CI) | p-Value |
| UCR            |            |          |            |          |            |          |            |          |
| Low UCR (<27.208) | 1.038 (1.018–1.059) | <0.001 | 1.030 (1.008–1.052) | 0.0071 | 1.031 (1.009–1.054) | 0.0062 | 1.038 (1.009–1.068) | 0.0102 |
| High UCR (≥27.208) | 3.611 (2.323–5.615) | <0.001 | 3.110 (1.937–4.995) | <0.001 | 2.979 (1.818–4.844) | <0.001 | 3.783 (1.959–7.305) | <0.001 |
| UCR            |            |          |            |          |            |          |            |          |
| Low UCR (<27.208) | 1.039 (1.008–1.071) | 0.0014 | 1.036 (1.033–1.070) | 0.0026 | 1.041 (1.066–1.078) | 0.0015 | 1.066 (1.011–1.124) | 0.0089 |
| High UCR (≥27.208) | 2.995 (1.540–5.671) | 0.0001 | 3.082 (1.515–6.271) | 0.0001 | 3.634 (1.673–7.892) | 0.0001 | 10.161 (2.691–38.368) | <0.001 |

OR, odds ratio; CI, confidence interval; PSM, propensity score matching; UCR, urea nitrogen to creatinine ratio.

Before PSM, as a continuous variable, the UCR was positively related to the in-hospital mortality (Crude Model: OR = 1.038, 95% CI: 1.018–1.059, p < 0.001; Model I: OR = 1.030, 95% CI: 1.008–1.052, p = 0.0071; Model II: OR = 1.031, 95% CI: 1.009–1.054, p = 0.0062; Model III: OR = 1.038, 95% CI: 1.009–1.068, p = 0.0102). Moreover, as a categorical variable, the in-hospital mortality increased remarkably for patients in the high UCR (≥27.208) group compared to the low UCR (<27.208) group (Crude Model: OR = 3.611, 95% CI: 2.323–5.615, p < 0.001; Model I: OR = 3.110, 95% CI: 1.937–4.995, p < 0.001; Model II: OR = 2.979, 95% CI: 1.818–4.844, p < 0.001; Model III: OR = 3.783, 95% CI: 1.959–7.305, p < 0.001) (Table 3).

Figure 2 displays the K–M curves of the two groups. The high UCR (≥27.208) group exhibited remarkably higher in-hospital mortality (Figure 2A) compared to the low UCR (<27.208) group (p < 0.001).

3.5. The Results of PSM

Considering that the two groups presented imbalanced baseline features, a 1:1 ratio PSM was completed to balance the latent confounders, which obtained 92 pairs of score-matched sufferers. The difference between the two groups were balanced in terms of nearly all variables, and a favorable matching performance was achieved (Figure 3).
Figure 2. Kaplan–Meier survival curves of in-hospital mortality classified into two groups according to UCR before (A) and after PSM (B). UCR, urea nitrogen to creatinine ratio.

Figure 3. The results of matching. A standardized mean difference (SMD) was used to examine the degree of PSM. A threshold of less than 0.1 was considered acceptable. PSM, propensity score matching [19]; weighted SMRW, weighted the standardized mortality ratio weighting [16]; weighted PA, weighted pairwise algorithmic [15]; weighted OW, weighted overlap weight [18]. MBP, mean blood pressure; DBP, diastolic blood pressure; RR, respiratory rate; INR, international normalized ratio; PT, prothrombin time.

3.6. The Clinical Characteristics of Non-Traumatic Subarachnoid Hemorrhage Patients after PSM

The clinical characteristics of non-traumatic subarachnoid hemorrhage patients after PSM are shown in Table 4. After PSM, the high UCR group ($\geq 27.208$) still presented obvious higher in-hospital mortality than the low UCR group (<27.208) (43.5 vs. 20.7%, respectively, $p < 0.001$) (Table 4).
Table 4. The clinical characteristics of non-traumatic subarachnoid hemorrhage after PSM.

| Characteristic                        | All Patients | Low UCR \(< 27.208\) | High UCR \(\geq 27.208\) | \(p\) |
|--------------------------------------|--------------|------------------------|---------------------------|------|
| N                                    | 184          | 92                     | 92                        |      |
| Demographic                          |              |                        |                           |      |
| Female, n (%)                        | 132 (71.7)   | 68 (73.9)              | 64 (69.6)                 | 0.513|
| Age, years                           | 72.0 (60.0, 81.0) | 72.0 (59.8, 81.0) | 72.5 (60.8, 80.0)         | 0.781|
| Ethnicity, n (%)                     |              |                        |                           | 0.092|
| Asian                                | 8 (4.3)      | 1 (1.1)                | 7 (7.6)                   |      |
| White                                | 113 (61.4)   | 57 (62)                | 56 (60.9)                 |      |
| Other                                | 63 (34.2)    | 34 (37)                | 29 (31.5)                 |      |
| Vital signs                           |              |                        |                           |      |
| HR, beats/minute                     | 79.5 (71.0, 90.0) | 78.5 (71.8, 88.2) | 81.5 (71.0, 92.2)         | 0.326|
| SBP, mmHg                            | 124.0 (116.0, 132.0) | 124.0 (115.8, 129.0) | 125.5 (116.0, 133.2)      | 0.489|
| DBP, mmHg                            | 61.0 (56.0, 66.2) | 62.0 (56.8, 67.0) | 60.0 (55.8, 66.0)         | 0.439|
| MBP, mmHg                            | 78.0 (74.0, 84.0) | 79.0 (74.0, 86.0) | 78.0 (74.8, 83.0)         | 0.878|
| Temperature, °C                      | 37.0 (36.7, 37.3) | 37.0 (36.8, 37.3) | 36.9 (36.7, 37.1)         | 0.152|
| SpO2, %                              | 97.0 (96.0, 99.0) | 97.0 (96.0, 99.0) | 97.0 (96.0, 99.0)         | 0.684|
| Comorbidities, n (%)                 |              |                        |                           |      |
| Myocardial infarction                | 21 (11.4)    | 11 (12)                | 10 (10.9)                 | 0.817|
| Congestive heart failure             | 32 (17.4)    | 15 (15.2)              | 18 (19.6)                 | 0.437|
| Peripheral vascular disease          | 12 (6.5)     | 7 (7.6)                | 5 (5.4)                   | 0.55 |
| Cerebrovascular disease              | 184 (100.0)  | 92 (100)               | 92 (100)                  | 1    |
| Dementia                             | 8 (4.3)      | 5 (5.4)                | 3 (3.3)                   | 0.72 |
| Paraplegia                           | 31 (16.8)    | 22 (23.9)              | 9 (9.8)                   | 0.01 |
| Renal disease                        | 28 (15.2)    | 13 (14.1)              | 15 (16.3)                 | 0.681|
| Malignant cancer                     | 11 (6.0)     | 4 (4.3)                | 7 (7.6)                   | 0.351|
| Mild liver disease                   | 12 (6.5)     | 4 (4.3)                | 8 (8.7)                   | 0.232|
| Diabetes                             | 54 (29.3)    | 26 (28.3)              | 28 (30.4)                 | 0.746|
| Hypertension                         | 4 (1.1)      | 2 (1.1)                | 2 (1.1)                   | 1    |
| DCI                                  | 7 (3.8)      | 5 (5.4)                | 2 (2.2)                   | 0.444|
| Sepsis                               | 103 (56.0)   | 50 (54.3)              | 53 (57.6)                 | 0.656|
| Vasospasm, n (%)                     | 6 (3.3)      | 3 (3.3)                | 3 (3.3)                   | 1    |
| Laboratory results                   |              |                        |                           |      |
| Hemoglobin, g/L                      | 12.4 (10.9, 13.6) | 12.6 (11.4, 13.3) | 12.3 (10.7, 13.7)         | 0.680|
| Platelets, 10^9/L                    | 210.0 (159.0, 255.2) | 209.0 (162.5, 265.0) | 210.0 (156.8, 251.2)      | 0.468|
| WBC, 10^9/L                          | 13.2 (10.2, 17.1) | 13.3 (10.5, 16.9) | 12.8 (10.0, 17.2)         | 0.986|
| Anion gap, mmol/L                    | 16.0 (14.0, 18.2) | 16.5 (14.0, 18.0) | 16.0 (14.0, 19.0)         | 0.605|
| Bicarbonate, mmol/L                  | 25.0 (22.0, 26.0) | 25.0 (22.0, 27.0) | 25.0 (23.0, 26.0)         | 0.293|
| Calcium, mg/dL                       | 8.8 (8.3, 9.3) | 8.8 (8.3, 9.3)        | 8.8 (8.3, 9.3)            | 0.964|
| Chloride, mmol/L                     | 107.0 (103.0, 111.0) | 108.0 (104.0, 109.2) | 107.0 (103.0, 112.2)      | 0.970|
| Sodium, mmol/L                       | 141.0 (139.0, 144.0) | 141.0 (139.0, 144.0) | 141.0 (138.0, 146.0)      | 0.826|
| INR                                  | 1.2 (1.1, 1.3) | 1.2 (1.1, 1.3)        | 1.2 (1.1, 1.3)            | 0.990|
| PT, s                                | 13.2 (11.9, 14.9) | 13.3 (11.9, 14.8) | 13.2 (12.0, 14.9)         | 1.000|
| APTT, s                              | 29.2 (26.5, 34.1) | 29.1 (26.4, 34.0) | 29.4 (26.6, 34.4)         | 0.847|
| ALT, IU/L                            | 78.0 (25.0, 78.0) | 78.0 (22.2, 78.0) | 78.0 (31.0, 78.0)         | 0.417|
| AST, U/L                             | 127.0 (36.8, 127.0) | 127.0 (35.8, 127.0) | 127.0 (42.8, 127.0)       | 0.146|
| Glucose, mg/dL                       | 138.5 (117.3, 169.2) | 141.6 (116.4, 166.9) | 135.1 (118.6, 169.2)      | 0.833|
| Scores                               |              |                        |                           |      |
| SOFA                                 | 3.0 (2.8, 3.0) | 3.0 (2.8, 3.0)        | 3.0 (2.8, 3.0)            | 0.863|
| GCS                                  | 10.0 (7.0, 14.0) | 10.0 (7.0, 14.0) | 9.0 (6.0, 13.0)           | 0.161|
| OASIS                                | 37.0 (29.0, 44.0) | 36.5 (29.0, 44.0) | 37.0 (29.0, 43.5)         | 0.600|
| WFNS, n (%)                          |              |                        |                           | 0.142|
| I                                    | 27 (14.7)    | 14 (15.2)              | 13 (14.1)                 |      |
| II                                   | 40 (21.7)    | 24 (26.1)              | 16 (17.4)                 |      |
| III                                  | 3 (1.6)      | 0 (0)                  | 3 (3.3)                   |      |
| IV                                   | 49 (26.6)    | 27 (29.3)              | 22 (23.9)                 |      |
| V                                    | 65 (35.3)    | 27 (29.3)              | 38 (41.3)                 |      |
Table 4. Cont.

| Characteristic                 | After PSM                      |
|-------------------------------|-------------------------------|
|                               | All Patients                  | Low UCR < 27.208 | High UCR ≥ 27.208 | p    |
| Outcomes                      |                               |                  |                   |      |
| In-hospital mortality, n (%)  | 59 (32.1)                     | 19 (20.7)        | 40 (43.5)         | < 0.001 |
| Length of ICU stay, days      | 6.0 (3.0, 13.0)               | 6.0 (3.0, 13.2)  | 6.0 (2.0, 12.0)   | 0.321  |
| Length of hospital stay, days | 11.0 (5.0, 19.2)              | 11.5 (6.0, 21.0) | 10.5 (5.0, 18.2)  | 0.449  |

3.7. Association between UCR and in-Hospital Mortality in Non-Traumatic Subarachnoid Hemorrhage Patients after PSM

After PSM, as a continuous variable, the UCR was still positively related to the in-hospital mortality (Crude Model: OR = 1.039, 95% CI: 1.008–1.071, p = 0.0014; Model I: OR = 1.036, 95% CI: 1.003–1.070, p = 0.0326; Model II: OR = 1.041, 95% CI: 1.006–1.078, p = 0.0215; Model III: OR = 1.0661, 95% CI: 1.011–1.124, p = 0.0189) (Table 3).

As a categorical variable, the in-hospital mortality still increased remarkably for patients in the high UCR (≥27.208) group compared to the low UCR (<27.208) group (Crude model: OR = 2.995, 95% CI: 1.540–5.671, p = 0.011; Model I: OR = 3.082, 95% CI: 1.515–6.271, p = 0.019; Model II: OR = 3.634, 95% CI: 1.673–7.892, p = 0.0011; Model III: OR = 10.161, 95% CI: 2.691–38.368, p < 0.001) (Table 3).

Figure 2 displays the Kaplan–Meier survival curves for the two groups. After PSM, the high UCR (≥27.208) group still exhibited an obviously higher in-hospital mortality (Figure 2B) compared to the low UCR (<27.208) group (p = 0.004).

Furthermore, the association of two groups remained stable after PSM analyses using SMRW, PA, OW and adjusted propensity score. The values of the ORs were in the range of 2.43–2.594 and all p < 0.05 (Table 5).

Table 5. Associations between UCR and in-hospital mortality in the crude analysis, multivariable analysis, and propensity-score analyses.

| Analysis                        | In-Hospital Mortality | p Value |
|---------------------------------|-----------------------|---------|
| No. of results/no. of patients at risk (%) |                       | <0.001  |
| Low UCR (<27.208)               | 148/865 (17.1)        |         |
| High UCR (≥27.208)              | 41/96 (42.7)          |         |
| Crude analysis-odds ratio (95% CI) | 3.611 (2.323–5.615)   | <0.001  |
| Multivariable analysis-odds ratio (95% CI) | 2.663 (1.627–4.359)   | <0.001  |
| Adjusted propensity score       | 2.594 (1.615–4.164)   | <0.001  |
| With SMRW                       | 2.536 (1.642–3.916)   | <0.001  |
| With PA                         | 2.502 (1.335–4.689)   | 0.0042  |
| With OW                         | 2.431 (1.203–4.912)   | 0.0133  |

PA, pairwise algorithmic; SMRW, standardized mortality ratio weight; OW, overlap weight. CI, confidence interval; UCR, urea nitrogen to creatinine ratio.

3.8. Subgroup Analysis

The subgroup analysis was conducted to determine how the UCR affected the in-hospital mortality from various perspectives including age (<65 and ≥65 years old), sex, myocardial infarction, congestive heart failure, peripheral vascular disease, chronic pulmonary disease, renal disease, malignant cancer, mild liver disease, diabetes, SOFA (<3 and ≥3), sepsis, and WFNS grade (Figure 4). The high UCR (≥27.208) group presented a higher in-hospital mortality rate compared to the low UCR (<27.208) group in all subgroups. We analyzed the interactions between UCR and all subgroup factors and found no obvious interaction (p > 0.05).
Table 1. The relationship between the UCR and in-hospital mortality in subgroup analysis.

| Subgroup                  | No. of patients | Mortality (%) | UCR > 27.208, OR (95% CI) | \( p \) for interaction |
|---------------------------|-----------------|---------------|----------------------------|--------------------------|
| Overall                   |                 |               |                            |                          |
| Crude                     |                 | 3.611 (2.323–5.615) |                            |                          |
| Adjusted                  |                 | 3.783 (1.959–7.305) |                            |                          |
| Age                       |                 |               |                            |                          |
| <65                       | 583             | 80 (13.7)     | 1.618 (0.640–4.091)       | 0.128                    |
| ≥65                       | 378             | 109 (28.8)    | 3.631 (2.096–6.289)       |                          |
| Gender                    |                 |               |                            |                          |
| Male                      | 423             | 89 (21)       | 2.736 (1.265–5.919)       | 0.317                    |
| Female                    | 538             | 100 (18.6)    | 4.427 (2.560–8.455)       |                          |
| Myocardial infarct        |                 |               |                            |                          |
| No                        | 881             | 165 (18.7)    | 3.747 (2.331–6.021)       |                          |
| Yes                       | 80              | 24 (30)       | 2.333 (0.681–7.879)       |                          |
| Congestive heart failure  |                 |               |                            |                          |
| No                        | 873             | 162 (18.6)    | 3.227 (1.952–5.334)       | 0.685                    |
| Yes                       | 88              | 27 (30.7)     | 4.08 (1.475–11.289)       |                          |
| Peripheral vascular disease|                |               |                            |                          |
| No                        | 868             | 175 (20.2)    | 3.535 (2.244–5.569)       | 0.856                    |
| Yes                       | 93              | 14 (15.1)     | 4.222 (0.638–27.948)      |                          |
| Chronic pulmonary disease |                 |               |                            |                          |
| No                        | 820             | 153 (18.7)    | 3.010 (1.840–4.924)       | 0.082                    |
| Yes                       | 141             | 36 (25.5)     | 8.000 (2.802–27.637)      |                          |
| Renal disease             |                 |               |                            |                          |
| No                        | 884             | 157 (17.8)    | 3.790 (2.322–6.185)       | 0.141                    |
| Yes                       | 77              | 32 (41.6)     | 1.565 (0.541–4.526)       |                          |
| Malignant cancer          |                 |               |                            |                          |
| No                        | 924             | 178 (19.3)    | 3.778 (2.387–5.981)       | 0.312                    |
| Yes                       | 37              | 11 (29.7)     | 1.575 (0.303–8.175)       |                          |
| Mild liver disease        |                 |               |                            |                          |
| No                        | 918             | 169 (18.4)    | 3.626 (2.262–5.769)       | 0.565                    |
| Yes                       | 43              | 20 (46.5)     | 2.222 (0.455–10.791)      |                          |
| Diabetes                  |                 |               |                            |                          |
| No                        | 800             | 149 (18.6)    | 3.673 (2.156–6.257)       | 0.725                    |
| Yes                       | 161             | 40 (24.8)     | 3.081 (1.357–6.998)       |                          |
| SOFA                      |                 |               |                            |                          |
| <3                        | 252             | 53 (21)       | 4.561 (1.913–10.872)      | 0.546                    |
| ≥3                        | 709             | 138 (19.2)    | 3.341 (1.997–5.559)       |                          |
| Sepsis                    |                 |               |                            |                          |
| No                        | 475             | 57 (12)       | 3.331 (1.555–7.132)       | 0.889                    |
| Yes                       | 486             | 132 (27.2)    | 3.562 (2.024–6.270)       |                          |
| WFNS                      |                 |               |                            |                          |
| I                         | 152             | 52 (34.2)     | 2.846 (0.932–8.708)       | 0.332                    |
| II                        | 315             | 7 (2.2)       | 6.847 (1.237–37.904)      |                          |
| III                       | 14              | 0 (0)         | 1 (0–Inf)                 |                          |
| IV                        | 212             | 26 (12.3)     | 4.200 (1.523–11.595)      |                          |
| V                         | 268             | 104 (38.6)    | 3.214 (1.576–6.555)       |                          |

Figure 4. The relationship between the UCR and in-hospital mortality in subgroup analysis. CI, confidence interval; UCR, urea nitrogen to creatinine ratio; WFNS, World Federation of Neurosurgical Societies.
4. Discussion

This study included 961 patients with non-traumatic subarachnoid hemorrhage whose information was extracted from the MIMIC-IV database. We performed univariable regression analysis, multivariable regression analysis, and PSM to reduce interference from possible confounding factors on in-hospital mortality. This large, retrospective cohort study suggested that, as a categorical or continuous variable, patients with high levels of UCR were more likely to have a higher risk of in-hospital mortality than patients with low levels of UCR. Furthermore, we found that the serum UCR level and in-hospital mortality had no interaction between subgroups. This is the first study to investigate the influence of the UCR on the prognosis of non-traumatic subarachnoid hemorrhage.

In the clinical environment, the UCR is a simple and commonly used index because it only requires venous blood, which is why the BUN is routinely measured in subarachnoid hemorrhage patients admitted to the ICU. Therefore, previous studies have explored the relationship between the serum BUN level and the worse prognosis of severe patients. Deng et al. conducted a study of 1738 acute ischemic stroke patients and found that higher UCR levels were related to a higher risk of poor three-month outcomes [20]. The study by Smita Mohanty et al. demonstrated that a level of UCR > 15 at admission was a significant independent predictor for neurological deterioration in ischemic stroke patients [21]. In addition, Zhu et al. conducted a study of 509 hospitalized patients with acute heart failure and determined that UCR was an independent predictor of all-cause mortality and that elevated UCR was related to poor prognosis [22]. Moreover, Han et al. used the MIMIC-III to determine the relationship between UCR and all-cause mortality in septic shock patients and found that a higher UCR was associated with increased mortality in these patients [8]. All the above results indicate that a higher UCR is associated with more serious conditions than a lower UCR. Our results are consistent with the above findings. This retrospective cohort study involved 961 patients, and the cut-off value of the UCR was considered to divide them into two groups. Compared with low UCR group, high UCR group exhibited higher in-hospital mortality (17.1 vs. 42.7%, respectively, \(p < 0.001\)). After adjustments for the confounding factors, our multivariable logistic regression analysis revealed that the in-hospital mortality for the high UCR (≥27.208) group remained higher than for the low UCR (<27.208) group both before and after PSM.

It is hard to identify the exact mechanisms behind the close correlation between serum UCR and in-hospital mortality in patients with subarachnoid hemorrhage. However, we can propose several hypothesized mechanisms to explain the relationship. Firstly, subarachnoid hemorrhage usually triggers a stress response in the body, which can lead to a disorder in the internal environment. Furthermore, unstable blood flow of the brain and kidney will lead to the change of BUN and creatinine. Secondly, previous studies suggested that the UCR was a routinely available indicator of hydration [10,23]. Dehydration is a very common phenomenon in ischemic stroke and hemorrhagic stroke, which is related to a high risk of poor outcomes at hospital discharge [24]. In the early stage of subarachnoid hemorrhage, consciousness disorder or dysphagia are the main causes of dehydration, which may lead to aggravation of the disease.

Our research has the following advantages: (1) a large sample size and improved statistical reliability and (2) the missing value of UCR was low, which may reduce the selection bias. In addition, the findings of our study may help clinicians identify high-risk patients with non-traumatic subarachnoid hemorrhage. Despite the value of our findings, there were still some limitations. First, this was a single-center study, and multicenter studies are necessary to verify the accuracy of our conclusions. Second, the data on the UCR were collected during the first 24 h of the patient’s admission to the ICU and the dynamic changes of UCR could not be analyzed. Third, the optimal cut-off value of the UCR was calculated using ROC curve analysis, with the maximum Youden index used to predict the survival status. The UCR was considered applicable to divide patients into a low UCR (<27.208) group and a high UCR (≥27.208) group. However, the AUC was 0.564.
(95% CI, 0.515–0.613), which was lower than expected. Therefore, it is necessary to verify the results through further studies.

5. Conclusions

In conclusion, this was the first study to investigate the prognostic significance of the UCR in non-traumatic subarachnoid hemorrhage patients. A high UCR was associated with a higher risk of in-hospital mortality than a low UCR. Therefore, the UCR can serve as a prognostic predictor of clinical outcomes in non-traumatic subarachnoid hemorrhage patients.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11237031/s1, Figure S1: The ROC curve of the UCR; Table S1: The best cut-off value, specificity, sensitivity, and Youden Index of UCR; Table S2: Univariable logistic regression analyses for in-hospital mortality in patients with non-traumatic subarachnoid hemorrhage.

Author Contributions: Conceptualization, J.W., Z.C., R.C. and J.Y.; methodology, J.W.; software, J.W.; validation, R.C., H.Y. and H.L.; formal analysis, J.W.; investigation, Z.C.; resources, H.L.; data curation, J.W.; writing—original draft preparation, Z.C.; writing—review and editing, J.Y.; visualization, H.L.; supervision, H.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study approval to access this database (Approval code, 45677587, approval date, 17 October 2021). The database was approved for research by the Massachusetts Institute of Technology (MIT) (No. 040300206) and the Beth Israel Deaconess Medical Center (No. 2001-P-001699/14) institutional review boards. We have also complied with all relevant ethical regulations regarding the use of the data for our study.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All data in the article can be obtained from the MIMIC-IV database (https://mimic.physionet.org/) (accessed on 17 October 2021).

Acknowledgments: The authors wish to thank the team of the Laboratory for Computational Physiology from the Massachusetts Institute of Technology (LCP-MIT) for keeping the MIMIC-IV databases available.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; RR, respiratory rate; SpO2, percutaneous oxygen saturation; DCI, delayed cerebral ischemia; UCR, BUN/creatinine; INR, international normalized ratio; PT, prothrombin time; APTT, activated partial thromboplastin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SOFA, sequential organ failure assessment score; GCS, Glasgow coma score; OASIS, oxford acute severity of illness score; ICU, Intensive care unit; WFNS, World Federation of Neurosurgical Societies.

References

1. Vergouwen, M.D.; Jong-Tjien-Fa, A.V.; Algra, A.; Rinkel, G.J. Time trends in causes of death after aneurysmal subarachnoid hemorrhage: A hospital-based study. Neurology 2016, 86, 59–63. [CrossRef] [PubMed]
2. Peng, R.; Liu, K.; Li, W.; Yuan, Y.; Niu, R.; Zhou, L.; Xiao, Y.; Gao, H.; Yang, H.; Zhang, C.; et al. Blood urea nitrogen, blood urea nitrogen to creatinine ratio and incident stroke: The Dongfeng-Tongji cohort. Atherosclerosis 2021, 333, 1–8. [CrossRef] [PubMed]
3. Chen, L.; Chen, L.; Zheng, H.; Wu, S.; Wang, S. The association of blood urea nitrogen levels upon emergency admission with mortality in acute exacerbation of chronic obstructive pulmonary disease. Chron. Respir. Dis. 2021, 18, 14799731211060051. [CrossRef] [PubMed]
4. Liu, E.Q.; Zeng, C.L. Blood Urea Nitrogen and In-Hospital Mortality in Critically Ill Patients with Cardiogenic Shock: Analysis of the MIMIC-III Database. Biomed. Res. Int. 2021, 2021, 5948636. [CrossRef] [PubMed]
5. Aronson, D.; Hammerman, H.; Beyar, R.; Yalonetsky, S.; Kapeliovich, M.; Markiewicz, W.; Goldberg, A. Serum blood urea nitrogen and long-term mortality in acute ST-elevation myocardial infarction. Int. J. Cardiol. 2008, 127, 380–385. [CrossRef] [PubMed]
6. Li, X.; Li, T.; Wang, J.; Dong, G.; Zhang, M.; Xu, Z.; Hu, Y.; Xie, B.; Yang, J.; Wang, Y. Higher blood urea nitrogen level is independently linked with the presence and severity of neonatal sepsis. Am. Med. 2021, 53, 2192–2198. [CrossRef] [PubMed]

7. Bacigalupo, A.; Oneto, R.; Bruno, B.; Soracco, M.; Lamparelli, T.; Gualandi, F.; Occhini, D.; Raiola, A.; Mordini, N.; Berisso, G.; et al. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): Blood urea nitrogen (BUN) and bilirubin. Bone Marrow Transpl. 1999, 24, 653–659. [CrossRef]

8. Han, D.; Zhang, L.; Zheng, S.; Xu, F.; Li, C.; Yang, R.; Ma, W.; Yin, H.; Lyu, J. Prognostic Value of Blood Urea Nitrogen/Creatinine Ratio for Septic Shock: An Analysis of the MIMIC-III Clinical Database. Biomed. Res. Int. 2021, 2021, 5995042. [CrossRef] [PubMed]

9. Jiang, W.F.; Deng, M.L. Prognostic impact of blood urea nitrogen/creatinine ratio changes in patients with acute ischemic stroke. Clin. Neurol. Neurosurg. 2022, 215, 107204. [CrossRef] [PubMed]

10. Lin, C.J.; Yang, J.T.; Huang, Y.C.; Tsai, Y.H.; Lee, M.H.; Lee, M.; Hsiao, C.T.; Hsiao, K.Y.; Lin, L.C. Favorable outcome of blood urea nitrogen/creatinine-based hydration therapy 3 months after acute ischemic stroke. Am. J. Emerg. Med. 2016, 34, 2414–2418. [CrossRef] [PubMed]

11. Matsue, Y.; van der Meer, P.; Damman, K.; Metra, M.; O'Connor, C.M.; Ponikowski, P.; Teerlink, J.R.; Cotter, G.; Davison, B.; Cleland, J.G.; et al. Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart 2017, 103, 407–413. [CrossRef] [PubMed]

12. Zhen, Z.; Liang, W.; Tan, W.; Dong, B.; Wu, Y.; Liu, C.; Xue, R. Prognostic significance of blood urea nitrogen/creatinine ratio in chronic HFpEF. Eur. J. Clin. Investig. 2022, 52, e13761. [CrossRef] [PubMed]

13. Johnson, A.; Bulgarelli, L.; Pollard, T.; Horng, S.; Celi, L.A.; Mark, R. MIMIC-IV (version 1.0). PhysioNet. 2021. Available online: https://physionet.org/content/mimiciv/1.0/ (accessed on 4 October 2022).

14. Skrivankova, V.V.; Richmond, R.C.; Woolf, B.A.R.; Yarmolinsky, J.; Davies, N.M.; Swanson, S.A.; VanderWeele, T.J.; Higgins, J.P.T.; Timpson, N.J.; Dimou, N.; et al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 2021, 326, 1614–1621. [CrossRef] [PubMed]

15. Li, L.; Greene, T. A weighting analogue to pair matching in propensity score analysis. Int. J. Biostat. 2013, 9, 215–234. [CrossRef] [PubMed]

16. Brookhart, M.A.; Wyss, R.; Layton, J.B.; Sturmer, T. Propensity score methods for confounding control in nonexperimental research. Circ. Cardiovasc. Qual. Outcomes 2013, 6, 604–611. [CrossRef] [PubMed]

17. Austin, P.C.; Stuart, E.A. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 2015, 34, 3661–3679. [CrossRef] [PubMed]

18. Cheng, C.; Li, F.; Thomas, L.E.; Li, F.F. Addressing Extreme Propensity Scores in Estimating Counterfactual Survival Functions via the Overlap Weights. Am. J. Epidemiol. 2022, 191, 1140–1151. [CrossRef]

19. Austin, P.C. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar. Behav. Res. 2011, 46, 399–424. [CrossRef] [PubMed]

20. Deng, L.; Wang, C.; Qiu, S.; Bian, H.; Wang, L.; Li, Y.; Wu, B.; Liu, M. Association between Blood Urea Nitrogen-to-creatinine Ratio and Three-Month Outcome in Patients with Acute Ischemic Stroke. Curr. Neuropsych. Res. 2019, 16, 166–172. [CrossRef]

21. Bhatia, K.; Mohanty, S.; Tripathi, B.K.; Gupta, B.; Mittal, M.K. Early predictors of early neurological deterioration in patients with acute ischaemic stroke with special reference to blood urea nitrogen (BUN)/creatinine ratio & urine specific gravity. Indian J. Med. Res. 2015, 141, 299–307. [CrossRef] [PubMed]

22. Zhu, X.; Cheang, I.; Liao, S.; Wang, K.; Yao, W.; Yin, T.; Lu, X.; Zhou, Y.; Zhang, H.; Li, X. Blood Urea Nitrogen to Creatinine Ratio and Long-Term Mortality in Patients with Acute Heart Failure: A Prospective Cohort Study and Meta-Analysis. Cardiorenal Med. 2020, 10, 415–428. [CrossRef] [PubMed]

23. Lin, L.C.; Lee, J.D.; Hung, Y.C.; Chang, C.H.; Yang, J.T. Bun/creatinine ratio-based hydration for preventing stroke-in-evolution after acute ischemic stroke. Am. J. Emerg. Med. 2014, 32, 709–712. [CrossRef] [PubMed]

24. Cortes-Vicente, E.; Guisado-Alonso, D.; Delgado-Mederos, R.; Camps-Renom, P.; Prats-Sanchez, L.; Martinez-Domeno, A.; Marti-Fabregas, J. Frequency, Risk Factors, and Prognosis of Dehydration in Acute Stroke. Front. Neurol. 2019, 10, 305. [CrossRef] [PubMed]